Evidence-Based Use of Indomethacin and Ibuprofen in the Neonatal Intensive Care Unit

Clinics in Perinatology

Volumn 39, Issue 1, 2012, Pages 111-136

  Johnston, Palmer G ^a   Gillam Krakauer, Maria ^a   Fuller, M Paige ^b   Reese, Jeff ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hemodynamically significant PDA (hsPDA); Ibuprofen; Indomethacin; Intraventricular hemorrhage (IVH); Necrotizing enterocolitis (NEC); Patent ductus arteriosus (PDA); Prematurity; Spontaneous intestinal perforation (SIP)

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEXAMETHASONE; DICLOFENAC; DOPAMINE; ETODOLAC; ETORICOXIB; FENOPROFEN; FLURBIPROFEN; HYDROCORTISONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LUMIRACOXIB; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTAGLANDIN; ROFECOXIB; SALICYLATE SODIUM; SALICYLIC ACID; SULINDAC; UNINDEXED DRUG; VALDECOXIB;

ACUTE KIDNEY FAILURE; ARTERY LIGATION; BILIRUBIN BLOOD LEVEL; BLEEDING DISORDER; BLINDNESS; BLOOD PRESSURE FLUCTUATION; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN PERFUSION; BRAIN VENTRICLE DILATATION; CEREBRAL PALSY; CHRONIC LUNG DISEASE; COGNITIVE DEFECT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG STRUCTURE; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HEARING IMPAIRMENT; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; IMMATURITY; INTESTINE PERFORATION; KERNICTERUS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TUBULE FUNCTION; LUNG DYSPLASIA; LUNG HEMORRHAGE; MESENTERY BLOOD FLOW; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NECROTIZING ENTEROCOLITIS; NEPHROTOXICITY; NEWBORN INTENSIVE CARE; NONHUMAN; OLIGURIA; PATENT DUCTUS ARTERIOSUS; PERCEPTION DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROLENTAL FIBROPLASIA; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SMALL INTESTINE PERFORATION; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; VERY LOW BIRTH WEIGHT; VISUAL IMPAIRMENT; WATER RETENTION;

CYCLOOXYGENASE INHIBITORS; DUCTUS ARTERIOSUS, PATENT; EVIDENCE-BASED MEDICINE; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL;

EID: 84857072986     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2011.12.002     Document Type: Review

References (182)

1. Kluckow M., Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 2000, 137(1):68-72.
2. Cotton R.B., Stahlman M.T., Kovar I., et al. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr 1978, 92(3):467-473.
3. Ellison R.C., Peckham G.J., Lang P., et al. Evaluation of the preterm infant for patent ductus arteriosus. Pediatrics 1983, 71(3):364-372.
4. Koch J., Hensley G., Roy L., et al. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006, 117(4):1113-1121.
5. Arcilla R.A., Thilenius O.G., Ranniger K. Congestive heart failure from suspected ductal closure in utero. J Pediatr 1969, 75(1):74-78.
6. Friedman W.F., Hirschklau M.J., Printz M.P., et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 1976, 295(10):526-529.
7. Heymann M.A., Rudolph A.M., Silverman N.H. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976, 295(10):530-533.
8. Coceani F., Olley P.M., Bishai I., et al. Prostaglandins and the control of muscle tone in the ductus arteriosus. Adv Exp Med Biol 1977, 78:135-142.
9. Coceani F., White E., Bodach E., et al. Age-dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen. Can J Physiol Pharmacol 1979, 57(8):825-831.
10. Patel J., Marks K.A., Roberts I., et al. Ibuprofen treatment of patent ductus arteriosus. Lancet 1995, 346(8969):255.
11. Van Overmeire B., Follens I., Hartmann S., et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child 1997, 76(3):F179-F184.
12. Varvarigou A., Bardin C.L., Beharry K., et al. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA 1996, 275(7):539-544.
13. Dubois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J 1998, 12(12):1063-1073.
14. Hammerman C. Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol 1995, 22(2):457-479.
15. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
16. Reese J., Dey S.K. Cyclooxygenases. Encyclopedia of molecular medicine 2002, 961-965. John Wiley & Sons, Inc, New York. 5th edition. H.H. Kazazian, G. Klein, H.W. Moser (Eds.).
17. Grosser T., Smyth E., FitzGerald G.A. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. Goodman & Gilmans's The pharmacological basis of therapeutics 2011, 959-1004. McGraw-Hill, New York (NY), Chapter 34. 12th edition. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
18. Romagnoli C., Bersani I., Rubortone S.A., et al. Current evidence on the safety profile of NSAIDs for the treatment of PDA. J Matern Fetal Neonatal Med 2011, 24(Suppl 3):10-13.
19. Smith W.L., Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001, 107(12):1491-1495.
20. Loftin C.D., Trivedi D.B., Tiano H.F., et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci U S A 2001, 98(3):1059-1064.
21. Trivedi D.B., Sugimoto Y., Loftin C.D. Attenuated cyclooxygenase-2 expression contributes to patent ductus arteriosus in preterm mice. Pediatr Res 2006, 60(6):669-674.
22. Reese J., Anderson J.D., Brown N., et al. Inhibition of cyclooxygenase isoforms in late- but not midgestation decreases contractility of the ductus arteriosus and prevents postnatal closure in mice. Am J Physiol Regul Integr Comp Physiol 2006, 291(6):R1717-R1723.
23. Rheinlaender C., Weber S.C., Sarioglu N., et al. Changing expression of cyclooxygenases and prostaglandin receptor EP4 during development of the human ductus arteriosus. Pediatr Res 2006, 60(3):270-275.
24. Groom K.M., Shennan A.H., Jones B.A., et al. TOCOX-a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk. BJOG 2005, 112(6):725-730.
25. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006, 116(1):4-15.
26. Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost 2006, 96(4):393-400.
27. Forsey J.T., Elmasry O.A., Martin R.P. Patent arterial duct. Orphanet J Rare Dis 2009, 4:17.
28. Warner T.D., Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004, 18(7):790-804.
29. Lehmann T., Day R.O., Brooks P.M. Toxicity of antirheumatic drugs. Med J Aust 1997, 166(7):378-383.
30. Malcolm D.D., Segar J.L., Robillard J.E., et al. Indomethacin compromises hemodynamics during positive-pressure ventilation, independently of prostanoids. J Appl Physiol 1993, 74(4):1672-1678.
31. Sagi S.A., Weggen S., Eriksen J., et al. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. J Biol Chem 2003, 278(34):31825-31830.
32. Tegeder I., Pfeilschifter J., Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001, 15(12):2057-2072.
33. Gersony W.M., Peckham G.J., Ellison R.C., et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983, 102(6):895-906.
34. Lago P., Bettiol T., Salvadori S., et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 2002, 161(4):202-207.
35. Linder N., Bello R., Hernandez A., et al. Treatment of patent ductus arteriosus: indomethacin or ibuprofen?. Am J Perinatol 2010, 27(5):399-404.
36. Merritt T.A., DiSessa T.G., Feldman B.H., et al. Closure of the patent ductus arteriosus with ligation and indomethacin: a consecutive experience. J Pediatr 1978, 93(4):639-646.
37. Merritt T.A., Harris J.P., Roghmann K., et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. J Pediatr 1981, 99(2):281-286.
38. Rudd P., Montanez P., Hallidie-Smith K., et al. Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Arch Dis Child 1983, 58(4):267-270.
39. Van Overmeire B., Smets K., Lecoutere D., et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000, 343(10):674-681.
40. Nemerofsky S.L., Parravicini E., Bateman D., et al. The ductus arteriosus rarely requires treatment in infants > 1000 grams. Am J Perinatol 2008, 25(10):661-666.
41. Su B.H., Lin H.C., Chiu H.Y., et al. Comparison of ibuprofen and indomethacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial. Arch Dis Child 2008, 93(2):F94-F99.
42. Weiss H., Cooper B., Brook M., et al. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr 1995, 127(3):466-471.
43. Chorne N., Jegatheesan P., Lin E., et al. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007, 151(6):629-634.
44. Hermes-DeSantis E.R., Clyman R.I. Patent ductus arteriosus: pathophysiology and management. J Perinatol 2006, 26(Suppl 1):S14-S18. [discussion: S22-3].
45. Kim E.S., Kim E.K., Choi C.W., et al. Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants. J Pediatr 2010, 157(5):745-750. e741.
46. Narayanan M., Cooper B., Weiss H., et al. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr 2000, 136(3):330-337.
47. Norton M.E., Merrill J., Cooper B.A., et al. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993, 329(22):1602-1607.
48. Quinn D., Cooper B., Clyman R.I. Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy. Pediatrics 2002, 110(1 Pt 1):e10.
49. Uchiyama A., Nagasawa H., Yamamoto Y., et al. Clinical aspects of very-low-birthweight infants showing reopening of ductus arteriosus. Pediatr Int 2011, 53(3):322-327.
50. Mahony L., Carnero V., Brett C., et al. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med 1982, 306(9):506-510.
51. Aranda J.V., Clyman R., Cox B., et al. A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. Am J Perinatol 2009, 26(3):235-245.
52. Su P.H., Chen J.Y., Su C.M., et al. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatr Int 2003, 45(6):665-670.
53. Ohlsson A., Walia R., Shah S.S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010, 4. CD003481.
54. Narayanan-Sankar M., Clyman R.I. Pharmacology review: pharmacological closure of patent ductus arteriosus in the neonate. NeoReviews 2003, 4:e215-e221.
55. Achanti B., Yeh T.F., Pildes R.S. Indomethacin therapy in infants with advanced postnatal age and patent ductus arteriosus. Clin Invest Med 1986, 9(4):250-253.
56. Seyberth H.W., Muller H., Wille L., et al. Recovery of prostaglandin production associated with reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome. Pediatr Pharmacol (New York) 1982, 2(2):127-141.
57. Herrera C., Holberton J., Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2007, 2. CD003480.
58. Hammerman C., Glaser J., Schimmel M.S., et al. Continuous versus multiple rapid infusions of indomethacin: effects on cerebral blood flow velocity. Pediatrics 1995, 95(2):244-248.
59. Christmann V., Liem K.D., Semmekrot B.A., et al. Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Paediatr 2002, 91(4):440-446.
60. Kuhl G., Seyberth H.W. Intestinal perforations after enteral administration of indomethacin in premature infants. J Pediatr 1986, 108(2):327-328.
61. Nagaraj H.S., Sandhu A.S., Cook L.N., et al. Gastrointestinal perforation following indomethacin therapy in very low birth weight infants. J Pediatr Surg 1981, 16(6):1003-1007.
62. Cooke R.W., Pickering D. Poor response to oral indomethacin therapy for persistent ductus arteriosus in very low birthweight infants. Br Heart J 1979, 41(3):301-303.
63. Alpan G., Eyal F., Vinograd I., et al. Localized intestinal perforations after enteral administration of indomethacin in premature infants. J Pediatr 1985, 106(2):277-281.
64. Marshall T.A., Pai S., Reddy P.P. Intestinal perforation following enteral administration of indomethacin. J Pediatr 1985, 107(3):484-485.
65. Bhat R., Vidyasagar D., Fisher E., et al. Pharmacokinetics of oral and intravenous indomethacin in preterm infants. Dev Pharmacol Ther 1980, 1(2-3):101-110.
66. Evans M., Bhat R., Vidyasagar D., et al. A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus. Pediatr Pharmacol (New York) 1981, 1(3):251-258.
67. Al Za'abi M., Donovan T., Tudehope D., et al. Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. Ther Drug Monit 2007, 29(6):807-814.
68. Aranda J.V., Varvarigou A., Beharry K., et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr 1997, 86(3):289-293.
69. Desfrere L., Zohar S., Morville P., et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005, 30(2):121-132.
70. Cherif A., Khrouf N., Jabnoun S., et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics 2008, 122(6):e1256-e1261.
71. Gokmen T., Erdeve O., Altug N., et al. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr 2011, 158(4):549-554. e541.
72. Sharma P.K., Garg S.K., Narang A. Pharmacokinetics of oral ibuprofen in premature infants. J Clin Pharmacol 2003, 43(9):968-973.
73. Barzilay B., Youngster I., Batash D., et al. Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants. Arch Dis Child 2011, [Epub ahead of print].
74. Gouyon J.B., Kibleur Y. Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants. Clin Ther 2010, 32(10):1740-1748.
75. Noori S., McCoy M., Friedlich P., et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009, 123(1):e138-e144.
76. Stark A.R., Carlo W.A., Tyson J.E., et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001, 344(2):95-101.
77. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004, 114(6):1649-1657.
78. Peltoniemi O., Kari M.A., Heinonen K., et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 2005, 146(5):632-637.
79. Attridge J.T., Clark R., Walker M.W., et al. New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. J Perinatol 2006, 26(2):93-99.
80. Kuhl G., Wille L., Bolkenius M., et al. Intestinal perforation associated with indomethacin treatment in premature infants. Eur J Pediatr 1985, 143(3):213-216.
81. Scholz T.D., McGuinness G.A. Localized intestinal perforation following intravenous indomethacin for patent ductus arteriosus. J Pediatr Gastroenterol Nutr 1988, 7(5):773-775.
82. Sharma R., Hudak M.L., Tepas J.J., et al. Prenatal or postnatal indomethacin exposure and neonatal gut injury associated with isolated intestinal perforation and necrotizing enterocolitis. J Perinatol 2010, 30(12):786-793.
83. Major C.A., Lewis D.F., Harding J.A., et al. Tocolysis with indomethacin increases the incidence of necrotizing enterocolitis in the low-birth-weight neonate. Am J Obstet Gynecol 1994, 170(1 Pt 1):102-106.
84. Vanhaesebrouck P., Thiery M., Leroy J.G., et al. Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. J Pediatr 1988, 113(4):738-743.
85. Gordon P.V., Swanson J.R., Clark R. Antenatal indomethacin is more likely associated with spontaneous intestinal perforation rather than NEC. Am J Obstet Gynecol 2008, 198(6):725. [author reply: 725-6].
86. Fowlie P.W., Davis P.G., McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010, 7. CD000174.
87. Cassady G., Crouse D.T., Kirklin J.W., et al. A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth. N Engl J Med 1989, 320(23):1511-1516.
88. Dollberg S., Lusky A., Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr 2005, 40(2):184-188.
89. Milner M.E., de la Monte S.M., Moore G.W., et al. Risk factors for developing and dying from necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 1986, 5(3):359-364.
90. Palder S.B., Schwartz M.Z., Tyson K.R., et al. Association of closure of patent ductus arteriosus and development of necrotizing enterocolitis. J Pediatr Surg 1988, 23(5):422-423.
91. Coombs R.C., Morgan M.E., Durbin G.M., et al. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child 1990, 65(10 Spec No):1067-1071.
92. Pezzati M., Vangi V., Biagiotti R., et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999, 135(6):733-738.
93. Shimada S., Kasai T., Konishi M., et al. Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant. J Pediatr 1994, 125(2):270-277.
94. Van Bel F., Van Zoeren D., Schipper J., et al. Effect of indomethacin on superior mesenteric artery blood flow velocity in preterm infants. J Pediatr 1990, 116(6):965-970.
95. Yanowitz T.D., Yao A.C., Werner J.C., et al. Effects of prophylactic low-dose indomethacin on hemodynamics in very low birth weight infants. J Pediatr 1998, 132(1):28-34.
96. Fujii A.M., Brown E., Mirochnick M., et al. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol 2002, 22(7):535-540.
97. Grosfeld J.L., Chaet M., Molinari F., et al. Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Ann Surg 1996, 224(3):350-355. [discussion: 355-7].
98. Rajadurai V.S., Yu V.Y. Intravenous indomethacin therapy in preterm neonates with patent ductus arteriosus. J Paediatr Child Health 1991, 27(6):370-375.
99. Ryder R.W., Shelton J.D., Guinan M.E. Necrotizing enterocolitis: a prospective multicenter investigation. Am J Epidemiol 1980, 112(1):113-123.
100. Sankaran K., Puckett B., Lee D.S., et al. Variations in incidence of necrotizing enterocolitis in Canadian neonatal intensive care units. J Pediatr Gastroenterol Nutr 2004, 39(4):366-372.
101. Schmidt B., Davis P., Moddemann D., et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001, 344(26):1966-1972.
102. Benitz W.E. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?. J Perinatol 2010, 30(4):241-252.
103. Bose C.L., Laughon M.M. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child 2007, 92(6):F498-F502.
104. Clyman R.I., Chorne N. Patent ductus arteriosus: evidence for and against treatment. J Pediatr 2007, 150(3):216-219.
105. Ohlsson A., Shah S.S. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2011, 7. CD004213.
106. Sangtawesin C., Sangtawesin V., Lertsutthiwong W., et al. Prophylaxis of symptomatic patent ductus arteriosus with oral ibuprofen in very low birth weight infants. J Med Assoc Thai 2008, 91(Suppl 3):S28-S34.
107. Sangtawesin V., Sangtawesin C., Raksasinborisut C., et al. Oral ibuprofen prophylaxis for symptomatic patent ductus arteriosus of prematurity. J Med Assoc Thai 2006, 89(3):314-321.
108. Romagnoli C., Zecca E., Papacci P., et al. Furosemide does not prevent indomethacin-induced renal side effects in preterm infants. Clin Pharmacol Ther 1997, 62(2):181-186.
109. Kushnir A., Pinheiro J.M. Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts. BMC Clin Pharmacol 2011, 11:8.
110. Katakam L.I., Cotten C.M., Goldberg R.N., et al. Safety and effectiveness of indomethacin versus ibuprofen for treatment of patent ductus arteriosus. Am J Perinatol 2010, 27(5):425-429.
111. Van Overmeire B., Allegaert K., Casaer A., et al. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2004, 364(9449):1945-1949.
112. Gournay V., Roze J.C., Kuster A., et al. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet 2004, 364(9449):1939-1944.
113. Bandstra E.S., Montalvo B.M., Goldberg R.N., et al. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pediatrics 1988, 82(4):533-542.
114. Vieux R., Desandes R., Boubred F., et al. Ibuprofen in very preterm infants impairs renal function for the first month of life. Pediatr Nephrol 2010, 25(2):267-274.
115. Cataldi L., Leone R., Moretti U., et al. Potential risk factors for the development of acute renal failure in preterm newborn infants: a case-control study. Arch Dis Child 2005, 90(6):F514-F519.
116. Cuzzolin L., Fanos V., Pinna B., et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006, 21(7):931-938.
117. Erdeve O., Sarici S.U., Sari E., et al. Oral-ibuprofen-induced acute renal failure in a preterm infant. Pediatr Nephrol 2008, 23(9):1565-1567.
118. Fanos V., Antonucci R., Zaffanello M. Ibuprofen and acute kidney injury in the newborn. Turk J Pediatr 2010, 52(3):231-238.
119. Tiker F., Yildirim S.V. Acute renal impairment after oral ibuprofen for medical closure of patent ductus arteriosus. Indian Pediatr 2007, 44(1):54-55.
120. Baenziger O., Waldvogel K., Ghelfi D., et al. Can dopamine prevent the renal side effects of indomethacin? A prospective randomized clinical study. Klin Padiatr 1999, 211(6):438-441.
121. Fajardo C.A., Whyte R.K., Steele B.T. Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus. J Pediatr 1992, 121(5 Pt 1):771-775.
122. Barrington K., Brion L.P. Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants. Cochrane Database Syst Rev 2002, 3. CD003213.
123. Ahlfors C.E. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr 2004, 144(3):386-388.
124. Rheinlaender C., Helfenstein D., Walch E., et al. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr 2009, 98(1):36-42.
125. Zecca E., Romagnoli C., De Carolis M.P., et al. Does ibuprofen increase neonatal hyperbilirubinemia?. Pediatrics 2009, 124(2):480-484.
126. Amin S.B., Miravalle N. Effect of ibuprofen on bilirubin-albumin binding affinity in premature infants. J Perinat Med 2011, 39(1):55-58.
127. Aranda J.V., Thomas R. Systematic review: intravenous ibuprofen in preterm newborns. Semin Perinatol 2006, 30(3):114-120.
128. Desfrere L., Thibaut C., Kibleur Y., et al. Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants. J Pediatr 2011, [Epub ahead of print].
129. Mosca F., Bray M., Lattanzio M., et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997, 131(4):549-554.
130. Patel J., Roberts I., Azzopardi D., et al. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000, 47(1):36-42.
131. Romagnoli C., De Carolis M.P., Papacci P., et al. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. Clin Pharmacol Ther 2000, 67(6):676-683.
132. Austin N.C., Pairaudeau P.W., Hames T.K., et al. Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants. Arch Dis Child 1992, 67(7 Spec No):851-854.
133. Benders M.J., Dorrepaal C.A., van de Bor M., et al. Acute effects of indomethacin on cerebral hemodynamics and oxygenation. Biol Neonate 1995, 68(2):91-99.
134. Edwards A.D., Wyatt J.S., Richardson C., et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet 1990, 335(8704):1491-1495.
135. Laudignon N., Chemtob S., Bard H., et al. Effect of indomethacin on cerebral blood flow velocity of premature newborns. Biol Neonate 1988, 54(5):254-262.
136. Ohlsson A., Bottu J., Govan J., et al. Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with a patent ductus arteriosus. Dev Pharmacol Ther 1993, 20(1-2):100-106.
137. Pryds O., Greisen G., Johansen K.H. Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus. Eur J Pediatr 1988, 147(3):315-316.
138. Simko A., Mardoum R., Merritt T.A., et al. Effects on cerebral blood flow velocities of slow and rapid infusion of indomethacin. J Perinatol 1994, 14(1):29-35.
139. Van Bel F., Van de Bor M., Stijnen T., et al. Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effect. Pediatrics 1989, 84(5):802-807.
140. Lemmers P.M., Toet M.C., van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics 2008, 121(1):142-147.
141. McCormick D.C., Edwards A.D., Brown G.C., et al. Effect of indomethacin on cerebral oxidized cytochrome oxidase in preterm infants. Pediatr Res 1993, 33(6):603-608.
142. Couser R.J., Hoekstra R.E., Ferrara T.B., et al. Neurodevelopmental follow-up at 36 months' corrected age of preterm infants treated with prophylactic indomethacin. Arch Pediatr Adolesc Med 2000, 154(6):598-602.
143. Ment L.R., Vohr B., Oh W., et al. Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 1996, 98(4 Pt 1):714-718.
144. Ment L.R., Vohr B., Allan W., et al. Outcome of children in the Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 2000, 105(3 Pt 1):485-491.
145. Ment L.R., Vohr B.R., Makuch R.W., et al. Prevention of intraventricular hemorrhage by indomethacin in male preterm infants. J Pediatr 2004, 145(6):832-834.
146. Vohr B.R., Allan W.C., Westerveld M., et al. School-age outcomes of very low birth weight infants in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics 2003, 111(4 Pt 1):e340-e346.
147. Clyman R.I., Saha S., Jobe A., et al. Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. J Pediatr 2007, 150(1):46-50. e42.
148. AlFaleh K. Indomethacin prophylaxis revisited: changing practice and supportive evidence. Acta Paediatr 2011, 100(5):641-646.
149. Lipman B., Serwer G.A., Brazy J.E. Abnormal cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatrics 1982, 69(6):778-781.
150. Ment L.R., Stewart W.B., Scott D.T., et al. Beagle puppy model of intraventricular hemorrhage: randomized indomethacin prevention trial. Neurology 1983, 33(2):179-184.
151. Ment L.R., Duncan C.C., Ehrenkranz R.A., et al. Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants. J Pediatr 1985, 107(6):937-943.
152. Ment L.R., Duncan C.C., Ehrenkranz R.A., et al. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. J Pediatr 1988, 112(6):948-955.
153. Bada H.S., Green R.S., Pourcyrous M., et al. Indomethacin reduces the risks of severe intraventricular hemorrhage. J Pediatr 1989, 115(4):631-637.
154. Hanigan W.C., Kennedy G., Roemisch F., et al. Administration of indomethacin for the prevention of periventricular-intraventricular hemorrhage in high-risk neonates. J Pediatr 1988, 112(6):941-947.
155. Krueger E., Mellander M., Bratton D., et al. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin. J Pediatr 1987, 111(5):749-754.
156. Ment L.R., Oh W., Ehrenkranz R.A., et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994, 93(4):543-550.
157. DeMauro S.B., Schmidt B., Roberts R.S. Why would a sane clinician not prescribe prophylactic indomethacin?. Acta Paediatr 2011, 100(5):636.
158. Shah S.S., Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2003, 2. CD004213.
159. Dani C., Bertini G., Pezzati M., et al. Prophylactic ibuprofen for the prevention of intraventricular hemorrhage among preterm infants: a multicenter, randomized study. Pediatrics 2005, 115(6):1529-1535.
160. Couser R.J., Ferrara T.B., Wright G.B., et al. Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room. J Pediatr 1996, 128(5 Pt 1):631-637.
161. Dani C., Bertini G., Reali M.F., et al. Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. Acta Paediatr 2000, 89(11):1369-1374.
162. De Carolis M.P., Romagnoli C., Polimeni V., et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr 2000, 159(5):364-368.
163. Bellini C., Campone F., Serra G. Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. CMAJ 2006, 174(13):1843-1844.
164. Tefft R.G. The impact of an early ibuprofen treatment protocol on the incidence of surgical ligation of the ductus arteriosus. Am J Perinatol 2010, 27(1):83-90.
165. Brash A.R., Hickey D.E., Graham T.P., et al. Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med 1981, 305(2):67-72.
166. Smyth J.M., Collier P.S., Darwish M., et al. Intravenous indomethacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. Br J Clin Pharmacol 2004, 58(3):249-258.
167. Yeh T.F., Achanti B., Patel H., et al. Indomethacin therapy in premature infants with patent ductus arteriosus-determination of therapeutic plasma levels. Dev Pharmacol Ther 1989, 12(4):169-178.
168. Knight D.B. Patent ductus arteriosus: how important to which babies?. Early Hum Dev 1992, 29(1-3):287-292.
169. Knight D.B. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 2001, 6(1):63-73.
170. Laughon M.M., Simmons M.A., Bose C.L. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated?. Curr Opin Pediatr 2004, 16(2):146-151.
171. Campbell M. Natural history of persistent ductus arteriosus. Br Heart J 1968, 30(1):4-13.
172. Dudell G.G., Gersony W.M. Patent ductus arteriosus in neonates with severe respiratory disease. J Pediatr 1984, 104(6):915-920.
173. Jacob J., Gluck L., DiSessa T., et al. The contribution of PDA in the neonate with severe RDS. J Pediatr 1980, 96(1):79-87.
174. Thibeault D.W., Emmanouilides G.C., Nelson R.J., et al. Patent ductus arteriosus complicating the respiratory distress syndrome in preterm infants. J Pediatr 1975, 86(1):120-126.
175. Cotton R.B., Stahlman M.T., Bender H.W., et al. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr 1978, 93(4):647-651.
176. Kaapa P., Lanning P., Koivisto M. Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatr Scand 1983, 72(2):179-184.
177. Alexander F., Chiu L., Kroh M., et al. Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus. J Pediatr Surg 2009, 44(1):112-117. [disscusion: 117].
178. Brooks J.M., Travadi J.N., Patole S.K., et al. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child 2005, 90(3):F235-F239.
179. Kaempf J.W., Wu Y.X., Kaempf A.J., et al. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants?. J Perinatol 2011, 1-5. Accessed November 11, 2011. 10.1038/jp.2011.102.
180. Herrman K., Bose C., Lewis K., et al. Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit. Arch Dis Child 2009, 94(1):F48-F50.
181. Jones L.J., Craven P.D., Attia J., et al. Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Arch Dis Child 2011, 96(1):F45-F52.
182. Hammerman C., Bin-Nun A., Markovitch E., et al. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics 2011, e1-e4. Accessed November 11, 2011. 10.1542/peds.2011-0359.